Obermatt
See Similar Stocks →

Ocular Therapeutix

NMQ:OCUL · US67576A1007
PharmaceuticalsSmall

360

21
Profit price70
Owner Earnings Yield1
Dividend Yield1
Price/Sales13
Price/Book7
Return on Capital9
Cash Return on Capital6
Return on Equity8
Profit margins4
Accruals81
Owner Earnings Margin4
Sales growth23
Profit Growth6
Long-Term EPS Growth54
Reinvestment51
Price momentum39
Debt load57
Refinancing60
Debt Payback1
Liquidity19
Analyst ratings51
Opinion Changes50
Price Target Upside98
Market mood83
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Ocular Therapeutix doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2006
Employees311
Websiteocutx.com
ISINUS67576A1007
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
OphthalmologyPain ManagementInflammationAllergyBiotechnologyHealth CareMedical Device

Description

Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI, also known as OTX-TKI, the company’s investigational product candidate for retinal disease, is an axitinib intravitreal hydro…

Analysis

Weak and unloved

Ocular Therapeutix, Inc. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is adequate. The company scores 4/20 on our value-creation score: not creating value. Analysts lean positive.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
16
2023202420252026

All-time high

83

Jan 2023

All-time low

16

Jun 2026

Average rank

34

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
13
12
34
46
Price/Earnings
71
30
30
30
Price/Book
7
42
5
20
Dividend Yield
1
1
1
1
Value (overall)
12
23
16
35

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Ocular Therapeutix with its peers
Neumora Therapeutics
NSQ:NMRA
9
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
EyePoint
NMQ:EYPT
34
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Abeona Therapeutics
NAQ:ABEO
89
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Harmony Biosciences Holdings
NMQ:HRMY
94
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Vericel
NMQ:VCEL
82
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
CalciMedica
NAQ:CALC
—
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →